- Conditions
- Obesity & Overweight, Mobility Disability, HOMA-IR
- Interventions
- Enobosarm, Semaglutide (Wegovy) weekly injection
- Drug
- Lead sponsor
- Veru Inc.
- Industry
- Eligibility
- 65 Years to 100 Years
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Doral, Florida • Miami, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 3,455
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Social Anxiety Disorder
- Interventions
- Vilazodone, Placebo
- Drug
- Lead sponsor
- The Medical Research Network
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- BAF312, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 1,651 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Berkeley, California • Los Angeles, California + 45 more
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
- Interventions
- Deucrictibant, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • San Diego, California + 5 more
- Conditions
- Chronic Cough
- Interventions
- Placebo, Gefapixant
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 27
- States / cities
- Litchfield Park, Arizona • Scottsdale, Arizona • La Mesa, California + 23 more
- Conditions
- Healthy
- Interventions
- SXC-2023, Placebo oral capsule
- Drug
- Lead sponsor
- Promentis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Schizophrenia
- Interventions
- AZD 8529, Risperidone, Placebo to match AZD8529, Placebo to match risperidone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Garden Grove, California • Glendale, California • Rockville, Maryland
- Conditions
- Overactive Bladder
- Interventions
- Lactobacillus Probiotic Capsule, Matching Lactobacillus Probiotic Placebo Capsule
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Hillsborough, North Carolina • Raleigh, North Carolina
- Conditions
- Methamphetamine Use Disorder
- Interventions
- Pomaglumetad methionil, Placebo, Methamphetamine
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Sleep-Disordered Breathing, Obstructive Sleep Apnea, Central Sleep Apnea, Chronic Pain, Opioid Use
- Interventions
- Acetazolamide, Placebo
- Drug · Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Charcot-Marie-Tooth Disease With Sorbitol Dehydrogenase Deficiency (CMT-SORD)
- Interventions
- Govorestat, Placebo Control
- Drug
- Lead sponsor
- Applied Therapeutics, Inc.
- Industry
- Eligibility
- 16 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Gordonville, Pennsylvania
- Conditions
- Asthma
- Interventions
- Lebrikizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 9
- States / cities
- Bakersfield, California • Long Beach, California • Miami, Florida + 6 more
- Conditions
- Long QT Syndrome
- Interventions
- GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Casopitant 150 mg, Ketoconazole, Casopitant 150 mg matching placebo, Casopitant 50 mg, Casopitant 50 mg matching placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 3
- States / cities
- Overland Park, Kansas • Buffalo, New York • Columbus, Ohio
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Orange, California • Palo Alto, California • San Francisco, California + 20 more
- Conditions
- Glioblastoma
- Interventions
- Galunisertib, Lomustine, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more
- Conditions
- Healthy Participants
- Interventions
- LY3009104, Placebo, moxifloxacin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Alcohol Use Disorder
- Interventions
- Dutasteride Capsules, Placebo Capsules
- Drug
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Norovirus Infections
- Interventions
- Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose, Placebo
- Drug
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 3
- States / cities
- Long Beach, California • Lenexa, Kansas • Saint Paul, Minnesota
- Conditions
- Hypertension
- Interventions
- Azilsartan medoxomil and olmesartan, Olmesartan, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 77 more
- Conditions
- Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
- Interventions
- Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor), Placebo bolus & placebo infusion, Placebo capsules - end of infusion, Placebo capsules - as soon as possible after randomization
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Colitis Ulcerative
- Interventions
- SAR441566, SAR441566 matching Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 19
- States / cities
- Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more
- Conditions
- Niemann-Pick Disease, Type C
- Interventions
- arimoclomol, Placebo
- Drug
- Lead sponsor
- ZevraDenmark
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 2
- States / cities
- Oakland, California • Rochester, Minnesota
- Conditions
- Type 2 Diabetes
- Interventions
- HP-211, Placebo
- Drug
- Lead sponsor
- Housey Healthcare ULC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 25
- States / cities
- Canoga Park, California • Doral, Florida • Edgewater, Florida + 21 more